(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 40.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Bridgebio Pharma's revenue in 2024 is $218,597,000.On average, 4 Wall Street analysts forecast BBIO's revenue for 2024 to be $31,575,629,945, with the lowest BBIO revenue forecast at $1,281,835,431, and the highest BBIO revenue forecast at $67,927,921,380. On average, 4 Wall Street analysts forecast BBIO's revenue for 2025 to be $58,138,254,143, with the lowest BBIO revenue forecast at $25,165,142,885, and the highest BBIO revenue forecast at $140,084,964,036.
In 2026, BBIO is forecast to generate $121,147,482,924 in revenue, with the lowest revenue forecast at $52,358,766,948 and the highest revenue forecast at $213,495,772,734.